BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21861206)

  • 1. Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results.
    Machaczka M; Wahlin BE; Piatkowska-Jakubas B; Rucinska M; Jurczak W; Balana-Nowak A; Klimkowska M; Hägglund H; Skotnicki AB
    Med Oncol; 2012 Sep; 29(3):2070-6. PubMed ID: 21861206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia.
    Poulain S; Lepelley P; Cambier N; Cosson A; Fenaux P; Wattel E
    Adv Exp Med Biol; 1999; 457():57-63. PubMed ID: 10500780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.
    da Silveira Júnior LS; Soares VL; Jardim da Silva AS; Gil EA; Pereira de Araújo MDG; Merces Gonçalves CA; Paiva AS; Moura de Oliveira TM; Oliveira GHM; Kramer Cavacanti E Silva DG; de Araújo Moura Lemos TM; Moretti Rebecchi IM; de Farias Sales VS; Luchessi AD; Cavalcanti Júnior GB
    Int J Lab Hematol; 2020 Oct; 42(5):594-603. PubMed ID: 32452631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients.
    Scheiner MA; da Cunha Vasconcelos F; da Matta RR; Dal Bello Figueira R; Maia RC
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):959-69. PubMed ID: 22358301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
    Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
    Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).
    Samdani A; Vijapurkar U; Grimm MA; Spier CS; Grogan TM; Glinsmann-Gibson BJ; List AF
    Leuk Res; 1996 Feb; 20(2):175-80. PubMed ID: 8628017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia.
    Filipits M; Pohl G; Stranzl T; Suchomel RW; Scheper RJ; Jäger U; Geissler K; Lechner K; Pirker R
    Blood; 1998 Mar; 91(5):1508-13. PubMed ID: 9473213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
    List AF; Kopecky KJ; Willman CL; Head DR; Persons DL; Slovak ML; Dorr R; Karanes C; Hynes HE; Doroshow JH; Shurafa M; Appelbaum FR
    Blood; 2001 Dec; 98(12):3212-20. PubMed ID: 11719356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival.
    Wood P; Burgess R; MacGregor A; Yin JA
    Br J Haematol; 1994 Jul; 87(3):509-14. PubMed ID: 7993790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
    Machaczka M; Rucińska M; Jabłoński M; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):407-13. PubMed ID: 10021886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
    Leith CP; Kopecky KJ; Chen IM; Eijdems L; Slovak ML; McConnell TS; Head DR; Weick J; Grever MR; Appelbaum FR; Willman CL
    Blood; 1999 Aug; 94(3):1086-99. PubMed ID: 10419902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
    Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia.
    Prijić S; Ugrina I; Labar B; Nemet D; Batinić J; Zadro R; Ries S; Gjadrov-Kuvedžić K; Davidović S; Batinić D
    Leuk Lymphoma; 2015; 56(8):2281-8. PubMed ID: 25426669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.
    Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
    Blood; 1998 Jun; 91(12):4480-8. PubMed ID: 9616142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia.
    Djunic I; Virijevic M; Djurasinovic V; Novkovic A; Colovic N; Kraguljac-Kurtovic N; Vidovic A; Suvajdzic-Vukovic N; Tomin D
    Med Oncol; 2012 Sep; 29(3):2077-82. PubMed ID: 22081445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
    Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
    Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.